GlassScriptPhysician profile
Susan M Zemitis
NPI 1093483505
$4,563.18
in general payments reported to CMS, 2019-2025
25 companies · $2,831 in 2025
The $2,831 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $125 · 2024: $1,607 · 2025: $2,831.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,438.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,438.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $996.60 | 2022-2025 | |
| Gilead Sciences, INC. | $674.88 | 2024-2025 | |
| Ardelyx, INC. | $414.35 | 2024-2025 | Ibsrela |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $311.97 | 2025 | Xifaxan |
| Pfizer INC. | $239.42 | 2024-2025 | |
| Ipsen Biopharmaceuticals, INC | $228.59 | 2024-2025 | Iqirvo, Bylvay |
| Takeda Pharmaceuticals U.S.A., INC. | $220.91 | 2024-2025 | Entyvio |
| Janssen Biotech, INC. | $156.51 | 2024-2025 | Tremfya, Stelara |
| Merck Sharp & Dohme LLC | $149.43 | 2024 | Dificid |
| Novo Nordisk INC | $140.50 | 2025 | Wegovy |
| Madrigal Pharmaceuticals | $130.39 | 2024-2025 | Resmetirom, Rezdiffra |
| Ethicon US, LLC | $130.14 | 2025 | Linx Reflux Management System |
| Regeneron Healthcare Solutions, INC. | $110.19 | 2024-2025 | Dupixent |
| Qol Medical, LLC | $100.30 | 2024-2025 | Sucraid, Sucraid |
| Lilly USA, LLC | $99.89 | 2025 | Omvoh |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $96.46 | 2024-2025 | Voquezna |
| Braintree Laboratories, INC. | $77.54 | 2024-2025 | Suflave, Sutab |
| Celgene Corporation | $62.08 | 2024 | Zeposia |
| Genzyme Corporation | $51.32 | 2025 | |
| Intercept Pharmaceuticals, INC. | $49.42 | 2024-2025 | |
| Organon LLC | $30.72 | 2025 | Hadlima |
| Exact Sciences Corporation | $27.96 | 2025 | The Cologuard Plus Collection Kit |
| Alnylam Pharmaceuticals INC. | $24.91 | 2025 | Givlaari |
| Pharmacosmos Therapeutics INC. | $20.00 | 2025 | Monoferric |
| Ironwood Pharmaceuticals, INC | $18.70 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Zemitis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.